Biotechnology - Anti-virals, Biotechnology

Filter

Current filters:

Anti-viralsBiotechnology

Popular Filters

1 to 25 of 194 results

National Institute of Allergy and Infectious Diseases launches ZMapp Ebola trial with Liberia

National Institute of Allergy and Infectious Diseases launches ZMapp Ebola trial with Liberia

02-03-2015

The USA’s National Institute of Allergy and Infectious Diseases has launched a clinical trial with…

Anti-viralsBiotechnologyLiberiaMapp BiopharmaceuticalResearchZMapp

Mylan to distribute Sovaldi and Harvoni in India

23-02-2015

US generics major Mylan said today that its Indian subsidiary has entered into an agreement with Gilead…

Anti-viralsBiotechnologyGileadHarvoniIndiaMarkets & MarketingMylanSovaldi

Gilead beats 4th-qtr 2014 expectations, as hepatitis C drug sales soar

Gilead beats 4th-qtr 2014 expectations, as hepatitis C drug sales soar

04-02-2015

US biotech firm Gilead Sciences posted fourth-quarter and full-year financial results after markets closed…

Anti-viralsBiotechnologyFinancialGilead SciencesHarvoniSovaldi

Chimerix to drop development of brincidofovir for Ebola

Chimerix to drop development of brincidofovir for Ebola

02-02-2015

US antiviral biopharma company Chimerix says that, after discussion with the US Food and Drug Administration,…

Anti-viralsBiotechnologybrincidofovirChimerixResearchTropical diseasesUSA

Valneva grants license to Immune Targeting Systems for the development of hepatitis B vaccine

Valneva grants license to Immune Targeting Systems for the development of hepatitis B vaccine

29-01-2015

France-based biotech firm Valneva and UK company Immune Targeting Systems (ITS) have signed an exclusive…

Anti-viralsBiotechnologyGlobalImmune Targeting SystemsLicensingValneva

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen

26-01-2015

US biotech major Gilead Sciences has expanded its hepatitis C generic licensing agreements to include…

Anti-viralsBiotechnologyGenericsGilead SciencesIndiaLicensingSovaldiUSA

UK NICE recommends hepatitis C drugs Sovaldi and Olysio

UK NICE recommends hepatitis C drugs Sovaldi and Olysio

16-01-2015

In final draft guidance issued today, England health costs watchdog the National Institute for Health…

Anti-viralsBiotechnologyGilead SciencesJanssenJohnson & JohnsonOlysioPricingRegulationSovaldiUK

Gilead denied patent for hepatitis C drug Sovaldi in India

Gilead denied patent for hepatitis C drug Sovaldi in India

15-01-2015

The Indian Patent Controller yesterday rejected one of US biotech major Gilead Sciences’ key patent…

Anti-viralsBiotechnologyGileadIndiaLegalPatentssofosbuvirSovaldi

Tekmira to merge with OnCore, to create major hep B company

Tekmira to merge with OnCore, to create major hep B company

14-01-2015

Shares of Tekmira Pharmaceuticals leapt as much as 50% after it announced a merger with privately-held…

Anti-viralsBiotechnologyOnCore BioPharmaOnCore BioPharmaTekmira PharmaceuticalsUSA

Merck & Co inks discovery and development deal with Moderna

Merck & Co inks discovery and development deal with Moderna

13-01-2015

Privately-held Moderna Therapeutics has entered into a license and collaboration agreement with US pharma…

Anti-viralsBiotechnologyFinancialMerck & CoModerna TherapeuticsResearchUSAVaccines

Cytos out-licenses VLP platform for hep B infections to OnCore Biopharma

06-01-2015

Switzerland-based Cytos Biotechnology has executed an exclusive license agreement granting privately-held…

Anti-viralsBiotechnologyCytos BiotechnologyLicensingOnCore BioPharma

Janssen and Gilead expand agreement to develop HIV single-tablet regimen

Janssen and Gilead expand agreement to develop HIV single-tablet regimen

29-12-2014

US health care giant Johnson & Johnson’s Ireland-based subsidiary Janssen R&D Ireland has amended its…

Anti-viralsBiotechnologyCompleraEuropeGileadJanssenPrezistaResearchTybost

NewLink Genetic and Merck Ebola collaboration gets $30 million government award

23-12-2014

US biotech firm NewLink Genetics saw its shares gain 4.1% to $40.11 in morning trading on Monday, following…

Anti-viralsBiotechnologyFinancialMerck & CoNewLink GeneticsResearchTropical diseasesUSA

CMC Biologics and OncoSynergy link on Ebola drug development and manufacture

CMC Biologics and OncoSynergy link on Ebola drug development and manufacture

16-12-2014

Denmark and USA-based contract manufacturers CMC Biologics and US biopharma start-up OncoSynergy have…

Anti-viralsBiotechnologyCMC BiologicsOncoSynergyOS2966ProductionResearchTropical diseases

US Class Action law suit challenges pricing of Gilead's hepatitis-C drug Sovaldi

US Class Action law suit challenges pricing of Gilead's hepatitis-C drug Sovaldi

10-12-2014

US law firm Chimicles & Tikellis of Haverford, PA, has filed a law suit on behalf of the Southeastern…

Anti-viralsBiotechnologyGilead SciencesLawLegalPricingSocial IssuesSovaldiUnited StatesUSA

US declaration under PREP Act to support Ebola vaccines development

10-12-2014

US Health and Human Services Secretary Sylvia Burwell yesterday announced a declaration under the Public…

Anti-viralsBavarian NordicBiotechnologyGlaxoSmithKlineJanssenJohnson & JohnsonLegalNewLink GeneticsResearchTropical diseasesUSAVaccines

Government action needed to slash prices for hepatitis C treatments, says US advocacy

Government action needed to slash prices for hepatitis C treatments, says US advocacy

04-12-2014

The US federal government should act to dramatically lower the cost of new and prohibitively pricey medications…

Anti-viralsBiotechnologyGilead SciencesPricingSovaldiUSA

Cocrystal Pharma and RFS Pharma complete merger

28-11-2014

USA-based biotech firm Cocrystal Pharma has announced the closing of its merger with RFS Pharma, a privately…

Anti-viralsBiotechnologyCocrystal PharmaMergers & AcquisitionsRFS Pharma

Merck gains rights to NewLink Genetics investigational Ebola vaccine

24-11-2014

US pharma giant Merck & Co has entered into an exclusive worldwide license agreement to research, develop,…

Anti-viralsBiotechnologyGlobalLicensingMerck & CoNewLink GeneticsResearchrVSV-EBOYTropical diseases

Gilead Sciences’ Harvoni gains EU approval

Gilead Sciences’ Harvoni gains EU approval

19-11-2014

The European Commission yesterday granted marketing authorization for US biotech antiviral specialists…

Anti-viralsBiotechnologyEuropeGilead SciencesHarvoniRegulationSovaldi

Scripps Research Institute scientists reveal weak spots in Ebola's defenses

18-11-2014

Scientists at The Scripps Research Institute (TSRI) have identified weak spots on the surface of Ebola…

Anti-viralsBiotechnologyMapp BiopharmaceuticalResearchTropical diseasesZMapp

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

10-11-2014

US surveyed specialists anticipate prescribing Gilead Sciences’ Harvoni to a high proportion of their…

Anti-viralsBiotechnologyGilead SciencesHarvoniJanssenMarkets & MarketingMedivirOlysioSovaldiUSA

Janssen’s Olysio/sofosbuvir combination cleared by FDA

Janssen’s Olysio/sofosbuvir combination cleared by FDA

06-11-2014

The Food and Drug Administration has approved US health care giant Johnson & Johnson's Olysio (simeprevir)…

Anti-viralsBiotechnologyJohnson & JohnsonMedivirOlysioRegulationsofosbuvirUSA

Department of Defense contracts Profectus to develop its VesiculoVax Zaire-Ebola virus vaccine

Department of Defense contracts Profectus to develop its VesiculoVax Zaire-Ebola virus vaccine

31-10-2014

The US Department of Defense has contracted the manufacture and IND-enabling preclinical testing of the…

Anti-viralsBiotechnologyProfectus BioSciencesResearchUSAVesiculoVax Zaire-Ebola

1 to 25 of 194 results

COMPANY SPOTLIGHT

Menarini

Back to top